The Combination of Molecular Hydrogen and Heme Oxygenase 1 Effectively Inhibits Neuropathy Caused by Paclitaxel in Mice.
Ignacio Martínez-Martel, Xue Bai, Rebecca Kordikowski, Christie R A Leite-Panissi, Olga Pol · Antioxidants (Basel, Switzerland) · 2024
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
The results indicated that the antiallodynic actions of the co-administration of CoPP plus HRW are more rapid and higher than those given by each of them when independently administered. These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how hydrogen-rich water affected the outcomes measured in male C57BL/6 mice. The results indicated that the antiallodynic actions of the co-administration of CoPP plus HRW are more rapid and higher than those given by each of them when independently administered.
What the Researchers Studied
The researchers studied male C57BL/6 mice. The study used a preclinical animal experiment. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 0.15 mM H₂ (≈0.302 mg/L). The results indicated that the antiallodynic actions of the co-administration of CoPP plus HRW are more rapid and higher than those given by each of them when independently administered. Membranes were posteriorly incubated overnight at 4 °C with the specific primary antibody anti-NLRP3 (1:200; AG-20B-0014-C100; Adipogen Life Sciences, Epalinges, Switzerland); 4-HNE (1:150; Abcam, AB4654; Cambridge, UK); NRF2 (1:100; Cell Signaling, mAb #12721; Technology, Danvers, MA, USA); HO-1 (1:150; ADI-SPA-895; Enzo Life Sciences, New York, NY, USA); glutathione sulfur transferase M1 (GSTM1; 1:150; NBP3-15037; Novus Biologic, Littleton, CO, USA); superoxide dismutase 1 (SOD-1; 1:150; NBP2-24915; Novus Biologic, Littleton, CO, USA); BACH1 (1:100; 14018-1-AP; Proteincech, Planegg-Martinsried, Germany) or anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 1:5000; AB516; Merck, Billerica, MA, USA) as a loading control.
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was male C57BL/6 mice. The study used a preclinical animal experiment. The hydrogen delivery method was hydrogen-rich water. The source-reported hydrogen concentration was 0.15 mM H₂ (≈0.302 mg/L).
Limitations and Safety
Safety information: This study supports the importance of HO-1 and H₂ systems in modulating PIPN and its accompanying mood disorders, and further suggests CoPP combined with HRW as a safe and effective alternative for its treatment.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.